Pfizer earnings fall on strong dollar, higher expenses

Pfizer reported a large drop in fourth-quarter earnings due to higher expenses and the strong dollar, but said it was on track to complete its takeover of Allergan. The results also included about $1.1 billion in sales from Pfizer's acquisition of Hospira, which specializes in injectable drugs. The company also notched large increases in selling, informational and administrative expenses, which includes marketing.